Castellano | Euskara | Français | English
DTB No 2: Safinamide. Xadago® for advanced Parkinson´s disease
Share it
ON Symptoms / LOW Evidence / OFF Medication
- Safinamide is a new selective monoamine oxidase B (MAO-B) inhibitor indicated for idiopatic Parkinson’s disease as a complementary treatment of levodopa alone or in combination with other drugs for Parkinson’s disease in patients with mid- or advanced-stage disease with fluctuations.
- Safinamide has been proven to be moderately superior to placebo in the mean daily time ON without dyskinesia. However, this drug has not been compared with other options such as selegiline or rasagiline.
- The mortality rate was significantly higher for patients receiving treatment with safinamide vs. placebo. Safinamide is contraindicated in patients with retinopathy and severe hepatic dysfunction.
- The effectiveness of safinamide cannot be determined due to the lack of data on the use of this drug for Parkinson’s disease. The benefit/risk balance of this drug has not been determined yet, since it has not been compared with other more widely used drugs.
